BIOHARVEST SCIENCES INC. ADDS DR. DENNIS GOODMAN TO ITS RECENTLY CREATED SCIENTIFIC ADVISORY BOARD

January 13, 2021

Vancouver, BC / January 13, 2021 / BioHarvest Sciences Inc. (the “Company” or “BioHarvest”) (CSE: BHSC) announces that it has created a new board of scientific advisors to assist the Company in capitalizing on its proprietary BioFarming technology. The mandate of the Scientific Advisory Board (“SAB”) is to advise and guide the Company as it expands the applications of its technology to broader medical applications and treatment arenas. Additionally, the SAB will advise the Company on best practices in conducting the required clinical trials to validate the efficacy of the Company’s products with these new forms of treatments

The Company is excited to announce that world renowned Dr. Dennis Goodman will join the SAB, which also includes Dr. David Brady (previously announced member of the Company’s Board of Advisors) and Dr. Yochi Hagay, co-founder and CTO of BioHarvest.

Dr. Goodman (M.D., F.A.C.C., F.A.C.P., F.C.C.P) brings over 40 years of relevant medical experience across multiple disciplines, including preventive cardiology. Dr. Goodman currently serves as Clinical Professor of Medicine at the New York School of Medicine, Professor of Medicine at the University of Cape Town, Director of Integrative Medicine and Preventive Cardiology at the New York School of Medicine. Professor Goodman has authored a number of scientific articles which have been published in peer reviewed journals as well as a number of abstracts. He has also authored three books focusing on the healing effects of specific ingredients such as Magnesium, Omega 3 and Vitamin K2. Dr. Goodman has participated in over 50 clinical trials and has extensive experience in providing advisory services in this highly technical area.

“Dr. Goodman’s acceptance of the Company’s invitation to join our Scientific Advisory Board is a clear validation of the company’s technology, its prospects and its disciplined approach to research and testing” said Ilan Sobel, CEO of the Company. “When you add a developed nutraceutical such as VINIA® to a pipeline of health and wellness-oriented products, including cannabinoids, one can project an array of clinical applications for such products. The Company’s Scientific Advisory Board will help guide the Company to the right applications and the appropriate scientific best practices to bring them to market. I am thrilled with such a significant addition to the team in the form of Dr. Goodman.” commented Mr. Sobel.

“Biotech innovation has always been a significant passion for me” said Dr. Goodman and added “One cannot ignore what BioHarvest is doing in the health and wellness space. Their BioFarming technology and the excellent team behind it is has the potential to transform the nutraceutical space. I look forward to working with the BioHarvest team to advance the benefits of the technology”.

Shareholders and Media are invited to register for the next BioHarvest Sciences Shareholder meeting, to be held at 11am PT/ 2pm ET Thursday, January 21. Interested parties can register at: https://app.livestorm.co/st-financial/bioharvest-sciences-shareholder-meeting.

 

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to also become a leading supplier of Cannabis for both medicinal and legal recreational purposes.

For more information visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

Our Blog

2024 CEO Letter to Shareholders

“Our goal is to accelerate the Botanical Synthesis movement that our team has wholly dedicated themselves to – driving forward innovation, our...

Read More

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications.

ABOUT BIOHARVEST SCIENCES INC.